How do you defeat an enemy you don’t understand, and who adapts to your every move? This is the serious challenge facing all modern medicine as doctors and scientists fight against antibiotic-resistant bacteria. As genetic sequencing has historically been too impractical to conduct for each patient’s infection, doctors typically apply antibiotics right away rather than wait to find out how dangerous the pathogen really is. However, this one-size-fits-all approach encourages the overuse of antibiotics, and antibiotic-resistant bacteria have become more prevalent across the globe. There is an urgent need for more precise application of antibiotics to cure infections without selecting for antibiotic resistant bacteria. But to do so, we need to understand how prescribing antibiotics affects microbial populations. And to do that, we need a lot of data.
A groundbreaking effort, led by a team of researchers at the University of Calgary, has used genomic technologies to generate a powerful data resource that could transform infection management in hospitals around the world. Their approach looks to genomics and beyond to understand how details of pathogens shape the progression of life-threatening infections.
Genomics involves the study of an organism’s entire genetic code, but what’s written in its DNA is only part of an organism’s biological story. The presence of specific proteins can tell researchers how the organism is performing core cellular functions, and the presence of metabolites – the end products of biochemical reactions – can help map out critical metabolic pathways. Thanks to advances in data collection and more powerful analytical tools, researchers can obtain a more holistic understanding of biological systems, adding proteomics and metabolomics—global views of the proteins and metabolites and organism produces—to their arsenal of “omics” approaches.
Knowing your enemy – not just their identity, but how they operate – is key to a good combat strategy, and the same is true for the battle against infectious disease. A multi-omics approach provides the insight needed to build molecular profiles of the pathogens that make us sick. Equipped with a deeper understanding of each bacterial strain at a molecular level, researchers can:
- Predict which pathogens will respond to antibiotics, helping doctors choose the most effective treatment right from the start.
- Monitor infectious disease outbreaks in hospitals, helping track and contain the spread of diseases earlier.
- Predict virulence in patients, helping doctors anticipate which pathogens will cause more serious illness.
Of course, building such profiles would require a monumental data collection and analysis effort. To enable this, the team created the Calgary Bloodstream Infection Cohort (CBSIC) to accomplish just such a task.
The CBSIC team collected microbial samples from over 38,000 cases of bloodstream infections from the past 17 years in the Calgary Health Zone. Leveraging their combined expertise in infectious diseases, microbiology, databases and data analytics, they collected state-of-the-art genomics, metabolomics and proteomics data to develop detailed biochemical profiles of each pathogen. Each pathogen profile was then linked to the medical records of the patient it had infected. This monumental effort resulted in the largest dataset of bloodstream infections in the world: ResistanceDB.
Using advanced artificial intelligence tools, the team has been able to determine which genes, proteins, metabolites and patient characteristics are linked to more severe infections. And that’s just the start – with such an enormous dataset and ever more powerful genomic tools, ResistanceDB will continue to produce new insights over time.
The vision is for clinicians to be able to match patients to the exact level of antibiotic therapy needed for their specific infection – an approach known as Precision Infection Management (PIM). Such approaches are expected to save costs by helping patients spend less time in the hospital, and most importantly, save lives. Genome Alberta support has enabled over $11M for the CBSIC team to advance implementation of a PIM strategy, which leverages the ResistanceDB data asset.
The long-term impact of this work may save thousands of Canadian lives. Researchers across North America are already using ResistanceDB to study how microbes are introduced and spread through populations, map the molecular cause of severe and repeating infections, develop new technology to automatically track the spread of diseases in hospitals and across the province, and assess how pathogens change in response to antibiotic use. These studies are providing the critical foundation for new generations of diagnostic tools that will automatically identify outbreaks of dangerous pathogens, enable more precise management of infections, and help policymakers craft new antibiotic stewardship programs.
Here in Alberta, the team are now working with Alberta Health Services’ Infection Prevention & Control team to assess the efficacy of real-time genomics outbreak monitoring. The hope is to better prevent the spread of hospital-acquired infections.
“The rise of antimicrobial resistant organisms poses a serious threat to modern medicine. The creation of ResistanceDB has been and will continue to be instrumental in supporting our stewardship and infection prevention and control efforts. It is very exciting to have this amazing global resource at our doorstep here in Alberta.”
John Conly, Medical Director, Infection Prevention and Control, Foothills Medical Centre, Alberta Health Services
The rising prevalence of antibiotic-resistant bacteria is a serious threat to the health and well-being of people around the world, but genomic technologies and data assets like ResistanceDB are helping turn the tide. Thanks to the efforts of research teams like CBSIC, there is growing hope for a future where infections are cured in less time and for less cost, ultimately saving more lives.